{
  "abstract": "Introduction Tafamidis improves outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) versus placebo. ATTR-CM has historically been considered a predominantly male disease, and women are underrepresented in prior studies. Sex-specific data in contemporary patients treated with tafamidis remain limited. Methods Data from two cohorts were pooled: an early-access cohort (NCT02791230) and patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS; NCT00628745) in 2019–2023. This analysis evaluated sex-related differences in clinical characteristics and all-cause mortality, adjusting for age, cohort, baseline New York Heart Association (NYHA) class, and wild-type (ATTRwt-CM) versus variant (ATTRv-CM) disease. Results Overall, 1924 patients treated with tafamidis were included (1476 from the early-access cohort and 448 from THAOS), of whom 214 (11.1%) were women. A smaller proportion of women than men had ATTRwt-CM (59.8% vs. 88.9%), whereas a greater proportion had ATTRv-CM (40.2% vs. 11.1%; p < 0.0001). Women were more frequently of African descent (23.9% vs. 7.4%; overall p < 0.001). Age at enrollment, age at symptom onset, and time from symptom onset to diagnosis were similar between sexes (p > 0.05). Women appeared more symptomatic at baseline, with a higher proportion in NYHA class III/IV (37.7% vs. 29.4%; overall p = 0.036) and classified as National Amyloidosis Centre stage II/III (68.1% vs. 47.7%; overall p = 0.023), despite similar N-terminal pro–B-type natriuretic peptide levels (p > 0.05). In adjusted analyses, women had a higher estimated glomerular filtration rate than men (β [men vs. women] = − 10.61; p < 0.001). Over a mean follow-up of 1.5 years, men had a higher risk of all-cause mortality than women (adjusted hazard ratio [men vs. women], 1.60, 95% CI 1.12–2.30). Conclusions In this analysis of contemporary patients with ATTR-CM treated with tafamidis, women represented a small proportion of the overall population, and a greater proportion had ATTRv-CM compared with men. Although women appeared more symptomatic at presentation, men had a higher risk of all-cause mortality. Trial Registration ClinicalTrials.gov identifiers: NCT02791230 and NCT00628745.",
  "abstract_shown": true,
  "affiliations": [
    "University College London",
    "Cardiology Division, Fondazione Toscana Gabriele Monasterio",
    "Mayo Clinic",
    "Complexo Hospitalario Universitario A Coruña, INIBIC and CIBERCV",
    "Columbia University Irving Medical Center",
    "University Hospital of Heidelberg",
    "Department of Cardiovascular Medicine, Cleveland Clinic",
    "Division of Cardiology, University Health Network",
    "Pfizer Inc",
    "Referral Center for Cardiac Amyloidosis, CHU Henri Mondor",
    "University of British Columbia"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 11,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Marianna Fontana"
    },
    {
      "affs": [
        1
      ],
      "name": "Alberto Aimo"
    },
    {
      "affs": [
        2
      ],
      "name": "Martha Grogan"
    },
    {
      "affs": [
        3
      ],
      "name": "Maria Generosa Crespo-Leiro"
    },
    {
      "affs": [
        4
      ],
      "name": "Mathew S. Maurer"
    },
    {
      "affs": [
        5
      ],
      "name": "Fabian aus dem Siepen"
    },
    {
      "affs": [
        6
      ],
      "name": "Mazen Hanna"
    },
    {
      "affs": [
        7
      ],
      "name": "Diego Delgado"
    },
    {
      "affs": [
        8
      ],
      "name": "Martin Carlsson"
    },
    {
      "affs": [
        9
      ],
      "name": "Thibaud Damy"
    },
    {
      "affs": [
        10
      ],
      "name": "Margot K. Davis"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/fnkgq0gy86xtq.bib",
  "cited_by": 0,
  "doi": "10.1007/s40119-026-00475-3",
  "fulltext_url": "https://doi.org/10.1007/s40119-026-00475-3",
  "id": "fnkgq0gy86xtq",
  "issns": [
    "2193-8261",
    "2193-6544"
  ],
  "landing_url": "https://doi.org/10.1007/s40119-026-00475-3",
  "language": "en",
  "licence": "CC-BY-NC",
  "licence_label": "CC BY-NC",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RC666-701"
    ],
    [
      "openalex",
      "1312|Amyloidosis: Diagnosis, Treatment, Outcomes"
    ]
  ],
  "openalex": "W7207553480",
  "pdf_url": "https://link.springer.com/content/pdf/10.1007/s40119-026-00475-3.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-09-01",
  "publisher": "Adis, Springer Healthcare",
  "ris": "https://research.draconitic.com/paper/fnkgq0gy86xtq.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T13:46:33Z",
      "native_id": "5a9e07922e1e4b44b84197646e3c1103",
      "source": "doaj",
      "url": "https://doi.org/10.1007/s40119-026-00475-3"
    }
  ],
  "subjects": [
    {
      "field": "biochemistry",
      "origin": "openalex:1312|Amyloidosis: Diagnosis, Treatment, Outcomes",
      "subfield": "molecular-biology"
    }
  ],
  "title": "Sex Differences in a Contemporary, Real-World Cohort of Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis",
  "title_text": "Sex Differences in a Contemporary, Real-World Cohort of Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T13:46:33Z",
  "url": "https://research.draconitic.com/paper/fnkgq0gy86xtq",
  "venue": "Cardiology and Therapy",
  "versions": []
}